| Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT05447910) | Mayo Clinic | 2022-07-21 |
| Breast Cancer Survivorship Biorepository (NCT05786664) | University of Southern California | 2022-04-11 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (NCT05319873) | Jonsson Comprehensive Cancer Center | 2022-04-07 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer (NCT05177796) | M.D. Anderson Cancer Center | 2022-03-11 |
| Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial (NCT04667481) | University of Washington | 2022-01-05 |
| An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors (NCT05012176) | Ohio State University Comprehensive Cancer Center | 2021-11-01 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer (NCT04959474) | Thomas Jefferson University | 2021-08-23 |
| Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer (NCT04897009) | Mayo Clinic | 2021-06-09 |
| Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases (NCT04647916) | SWOG Cancer Research Network | 2021-06-08 |
| Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer (NCT04481113) | OHSU Knight Cancer Institute | 2021-06-07 |
| Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer (NCT04871516) | Rutgers, The State University of New Jersey | 2021-05-18 |
| Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer (NCT05071677) | M.D. Anderson Cancer Center | 2021-05-03 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (NCT03606967) | National Cancer Institute (NCI) | 2021-04-13 |
| Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion (NCT05036083) | M.D. Anderson Cancer Center | 2021-03-19 |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (NCT04457596) | Alliance for Clinical Trials in Oncology | 2021-03-02 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| RBX7455 Before Surgery for the Treatment of Operable Breast Cancer (NCT04139993) | Mayo Clinic | 2020-08-31 |
| Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (NCT04294225) | Mayo Clinic | 2020-04-28 |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (NCT04266249) | ECOG-ACRIN Cancer Research Group | 2020-03-13 |
| Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (NCT04009044) | Northwestern University | 2020-02-17 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (NCT03554044) | University of California, San Francisco | 2020-02-05 |
| Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer (NCT03979508) | Mayo Clinic | 2020-01-10 |
| Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer (NCT03737695) | Mayo Clinic | 2019-09-16 |
| Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer (NCT04087057) | M.D. Anderson Cancer Center | 2019-08-23 |
| Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (NCT04001829) | ECOG-ACRIN Cancer Research Group | 2019-08-09 |
| Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer (NCT04022772) | M.D. Anderson Cancer Center | 2019-07-31 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (NCT03971409) | Laura Huppert, MD, BA | 2019-07-08 |
| Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery (NCT04169542) | M.D. Anderson Cancer Center | 2019-05-21 |
| A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity (NCT03789877) | Roswell Park Cancer Institute | 2019-01-16 |
| Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors (NCT02856503) | Eli Avisar, MD | 2019-01-13 |
| Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (NCT03238703) | Fred Hutchinson Cancer Center | 2018-09-01 |
| Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer (NCT03323658) | National Cancer Institute (NCI) | 2018-06-15 |
| Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer (NCT03518242) | Fred Hutchinson Cancer Center | 2018-06-06 |
| Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (NCT02876640) | National Cancer Institute (NCI) | 2018-03-16 |
| Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer (NCT03414970) | Alliance for Clinical Trials in Oncology | 2018-03-12 |
| Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer (NCT03345420) | University of Utah | 2017-12-12 |
| Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03359954) | M.D. Anderson Cancer Center | 2017-11-16 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (NCT03128619) | Jonsson Comprehensive Cancer Center | 2017-08-02 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer (NCT02860000) | Mayo Clinic | 2017-07-06 |
| Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (NCT02779855) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-02 |
| Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer (NCT02918474) | M.D. Anderson Cancer Center | 2017-04-28 |
| Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery (NCT03188393) | NRG Oncology | 2017-04-13 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (NCT02957968) | Virginia Commonwealth University | 2017-01-24 |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579) | M.D. Anderson Cancer Center | 2017-01-20 |
| Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (NCT02954874) | National Cancer Institute (NCI) | 2017-01-18 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer (NCT02876107) | M.D. Anderson Cancer Center | 2016-10-06 |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer (NCT02689427) | M.D. Anderson Cancer Center | 2016-09-22 |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT02453620) | National Cancer Institute (NCI) | 2016-02-12 |
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer (NCT02530489) | M.D. Anderson Cancer Center | 2016-02-04 |
| Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (NCT02456857) | M.D. Anderson Cancer Center | 2016-01-12 |
| Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative (NCT02276443) | M.D. Anderson Cancer Center | 2015-11-09 |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (NCT02445391) | ECOG-ACRIN Cancer Research Group | 2015-10-20 |
| Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery (NCT02526498) | Rutgers, The State University of New Jersey | 2015-07-15 |
| Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer (NCT02282345) | M.D. Anderson Cancer Center | 2015-04-16 |
| Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer (NCT02370277) | University of Southern California | 2014-12-16 |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (NCT02037529) | Academic and Community Cancer Research United | 2014-01-17 |
| Broccoli Sprout Extract in Treating Patients With Breast Cancer (NCT01753908) | Roswell Park Cancer Institute | 2013-05-21 |
| Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors (NCT01849250) | National Cancer Institute (NCI) | 2013-05-01 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091) | Mayo Clinic | 2013-04-09 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (NCT01750073) | University of Nebraska | 2012-12-07 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer (NCT01622868) | National Cancer Institute (NCI) | 2012-12-06 |
| Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (NCT01434303) | National Cancer Institute (NCI) | 2012-01-10 |
| Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer (NCT01334021) | M.D. Anderson Cancer Center | 2011-05-31 |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT01344031) | National Cancer Institute (NCI) | 2011-04-21 |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (NCT01272037) | National Cancer Institute (NCI) | 2011-02-28 |
| Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer (NCT01266642) | M.D. Anderson Cancer Center | 2011-02-08 |
| Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer (NCT01245712) | M.D. Anderson Cancer Center | 2010-11-15 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy (NCT00877500) | M.D. Anderson Cancer Center | 2009-03-30 |
| Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (NCT00601900) | National Cancer Institute (NCI) | 2008-09-24 |
| Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer (NCT00429182) | M.D. Anderson Cancer Center | 2007-06-01 |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer (NCT00477100) | M.D. Anderson Cancer Center | 2007-04-17 |
| Capecitabine in Women With Operable Breast Cancer (NCT00148720) | Dana-Farber Cancer Institute | 2004-09-01 |